Authors
Liangrui Pan, Chenchen Nie, Delin Nie, Bin Xie, Qiya Song, Ling Xiao, Qiankun Li, Jiayu Qian, Fanghua Hu, Xiong Peng, Yaning Yang, Zhihong Chen, Xiang Wang, Qingchun Liang, Yang Liu, Desheng Xiao
Published in
Cancer research. Nov 19, 2026. Epub Nov 19, 2026.
Abstract
Accurate prediction of treatment response remains challenging in cancer. To facilitate response prediction in non-small cell lung cancer (NSCLC), we developed PRISM, an interpretable multiscale graph-learning framework for estimating treatment-specific objective response from pretreatment H&E whole-slide images. PRISM integrated multiresolution tissue representations with a cell-level tumor microenvironment (TME) hypergraph, thereby treating higher-order microenvironmental organization as a learnable component of treatment-response prediction. Samples from 7,082 patients from four Chinese centers were screened. PRISM was evaluated across treatment specific cohorts receiving targeted therapy (T), EGFR-targeted therapy (T_EGFR), immune checkpoint inhibitor-based therapy (ICI), chemoimmunotherapy (CI), and chemotherapy (C) using patient-level internal cross-validation, independent multicenter external validation, and prospective silent validation. PRISM predicted early objective responses across prespecified systemic therapies in NSCLC. In comparison to 18 established multiple-instance learning and computational pathology baseline models, PRISM remained competitive, with numerical advantages in selected tasks. Multiscale attribution and exploratory H&E-derived TME analyses provided spatial context for model predictions. Overall, PRISM offers a morphology-based framework for estimating early response to prespecified systemic therapies and warrants further prospective multicenter evaluation.
PMID:
43055329
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0